Spero Therapeutics is a biopharmaceutical company developing a pipeline of novel treatments for bacterial infections. The Company’s pipeline of anti-infective agents is one of the most unique in the industry. Spero is pioneering an entirely new therapeutic platform called the Potentiator; this approach has yielded multiple molecules that enhance the utility and potency of many classes of existing drugs to include Gram-negative pathogens. Spero’s DHFR program is exploring the expansion of a novel antifolate’s antibacterial spectrum to treat trimethoprim resistance isolates including Gram-negative pathogens.